Compare Ascendis Pharma A/S (ASND) vs T Rowe Price Group Inc (TROW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs T Rowe Price Group Inc — how do they compare? Ascendis Pharma A/S trades at $255.5 (market cap $16.67B), while T Rowe Price Group Inc trades at $116.99 (market cap $24.26B). The key difference: T Rowe Price Group Inc is the larger of the two by market cap, and T Rowe Price Group Inc pays a 4.57% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | TROW | |
|---|---|---|
Market Cap | $16.67B | $24.26B |
Sector | Health | Financials |
52-Week High | $277.18 | $121.68 |
52-Week Low | $189.74 | $86.19 |
Enterprise Value | $17.04B | $21.46B |
Dividend Yield | — | 4.57% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About T Rowe Price Group Inc
T. Rowe Price provides asset-management services for individual and institutional investors. It offers a broad range of no-load U.S. and international stock, hybrid, bond, and money market funds. At the end of August 2022, the firm had $1.339 trillion in managed assets, composed of equity (54%), balanced (30%), fixed-income (13%), and alternatives (3%) offerings. Approximately two thirds of the company's managed assets are held in retirement-based accounts, which provides T. Rowe Price with a somewhat stickier client base than most of its peers. The firm also manages private accounts, provides retirement planning advice, and offers discount brokerage and trust services. The company is primarily a U.S.-based asset manager, deriving just under 10% of its AUM from overseas.
Read more on TROW →
